Smart Nanoparticle System Sheds Its Coating to Navigate Gut Barriers and Deliver Oral Liraglutide | Research

The takeaway

An auto-adaptive liposome system with a removable protein coating penetrated gut mucus 1.45x better and improved oral liraglutide absorption with significant blood sugar-lowering effects in animals.

1.45x mucus + 2.03x membrane penetration
The smart nanoparticle system improved mucus penetration by 1.45 times and membrane permeability by 2.03 times through its auto-adaptive surface-switching mechanism.

What the researchers found

The Pc-AT-CLs (protein corona-AT 1002-cationic liposomes) system demonstrated a two-stage adaptive delivery mechanism for oral liraglutide:

- Stage 1 (mucus penetration): BSA protein corona provided a hydrophilic, electrically neutral surface that reduced mucus adherence. Mucus penetration was 1.45 times greater than uncoated AT-CLs.

- Stage 2 (epithelial transport): After penetrating the mucus layer, the protein corona fell off, exposing the AT 1002 peptide and cationic surface. The apparent permeability coefficient (Papp) of AT-CLs was 2.03 times that of unmodified cationic liposomes.

In vivo testing showed significant hypoglycemic (blood sugar-lowering) effects and enhanced relative bioavailability compared to free liraglutide, confirming that the system protected liraglutide from degradation and improved its oral absorption.

Why it matters

Converting injectable peptide drugs like liraglutide into oral medications is one of the biggest challenges in drug delivery. While oral semaglutide exists, it requires specific fasting conditions and has limited bioavailability. This auto-adaptive system addresses the two main barriers to oral peptide delivery — mucus and epithelial cells — in sequence, using a single smart nanoparticle that adapts to each environment. If perfected, this approach could make oral delivery feasible for many peptide drugs currently requiring injection.

How the study worked

Researchers constructed cationic liposomes loaded with liraglutide, functionalized with AT 1002 (a tight junction-opening peptide), and coated with a BSA protein corona. Transmucus transport was tested using mucus barrier models. Transmembrane transport was assessed using intestinal cell permeability assays measuring apparent permeability coefficients. In vivo testing in rats evaluated hypoglycemic effects and oral bioavailability of the complete Pc-AT-CLs system compared to free liraglutide.

What this study cannot tell us

The study was conducted in rats, whose gut physiology differs from humans in mucus composition, transit time, and barrier thickness. Specific bioavailability percentages and dose comparisons are not detailed in the abstract. The BSA protein corona may trigger immune responses in humans. Manufacturing scalability and stability of the multi-component system were not addressed. The long-term safety of AT 1002 (which opens tight junctions between cells) is a concern, as this could potentially allow passage of unwanted substances. Comparison to the existing oral semaglutide formulation was not included.

How to read the evidence

This is a preclinical drug delivery study with systematic in vitro characterization (mucus and membrane transport) and in vivo validation (hypoglycemic effect in rats). The stepwise experimental design is rigorous for early-stage pharmaceutical research, but all results are in animal systems.

When this study was published

Published in 2024, this is a recent study in the active field of oral peptide drug delivery. The technology is at an early development stage with substantial optimization and testing needed before potential human use.

The bigger picture

Oral delivery of peptide drugs is considered the holy grail of pharmaceutical formulation. The global peptide drug market is valued at over $50 billion and growing, driven largely by GLP-1 agonists for diabetes and obesity. Most peptides still require injection, limiting patient compliance. This study demonstrates a sophisticated multi-barrier approach using biomimetic principles — the protein corona mimics the body's own surface modifications — that could generalize to other peptide drugs beyond liraglutide.

Questions still open

How does this delivery system compare in bioavailability to the existing oral semaglutide (Rybelsus) formulation?
Could this auto-adaptive liposome platform be generalized to deliver other injectable peptide drugs orally?
What are the long-term safety implications of repeatedly opening intestinal tight junctions with AT 1002?

Common questions

Why can't most peptide drugs be taken as pills?

Peptide drugs like liraglutide are proteins that get destroyed by stomach acid and digestive enzymes. Even if some survive, they struggle to cross two barriers in the intestine: a thick mucus layer that traps particles, and the tightly sealed cell layer underneath. This study created a smart nanoparticle that navigates both barriers in sequence by changing its surface properties as it travels through the gut.

How does the auto-adaptive system work?

The nanoparticle starts with a protein coating (albumin) that makes it slippery enough to pass through mucus. Once through, this coating naturally falls off, revealing a positively charged surface and a tight-junction-opening peptide (AT 1002) that help the particle cross the intestinal cell barrier. It's like a spacecraft shedding heat shields at different stages of re-entry.

Read the original research

Design of Auto-Adaptive Drug Delivery System for Effective Delivery of Peptide Drugs to Overcoming Mucus and Epithelial Barriers.

The AAPS journal, 26(5), 102

View on PubMed ↗Publisher’s paper ↗

Citation

Ding, Ruihuan; Li, Yanping; Zheng, Wei; Sun, Yiying; Zhao, Zhenyu; Zhang, Houqian; Yuan, Ranran; Wang, Aiping; Sun, Kaoxiang; Wang, Hongbo; Shi, Yanan. (2024). Design of Auto-Adaptive Drug Delivery System for Effective Delivery of Peptide Drugs to Overcoming Mucus and Epithelial Barriers.. The AAPS journal, 26(5), 102. https://doi.org/10.1208/s12248-024-00971-1